Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation
By Ian Walker
Sandoz Group said that it has reached agreement with Amgen in the patent dispute over the company's denosumab biosimilars products, paving the way for it to launch its bone treatments Jubbonti and Wyost in the U.S. by May 31.
The Swiss pharmaceutical company didn't disclose any terms of the agreement but said it doesn't impact previously disclosed guidance for this year. It said on March 31 that the company expects 2024 net sales to grow mid-single digit in constant currencies.
Sandoz received U.S. Food and Drug Administration approval for Wyost and Jubbonti--the first denosumab biosimilars to treat skeletal-related events and osteoporosis--on March 5.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
April 30, 2024 02:02 ET (06:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?